Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD + MTX/Ara-C + Rituximab in Untreated Mantle Cell Lymphoma
NCT00041132Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2002
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival. Started Sep 2002; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00041132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041132.